AU2020233452B2 - Salt of pentacyclic compound and crystals thereof - Google Patents

Salt of pentacyclic compound and crystals thereof Download PDF

Info

Publication number
AU2020233452B2
AU2020233452B2 AU2020233452A AU2020233452A AU2020233452B2 AU 2020233452 B2 AU2020233452 B2 AU 2020233452B2 AU 2020233452 A AU2020233452 A AU 2020233452A AU 2020233452 A AU2020233452 A AU 2020233452A AU 2020233452 B2 AU2020233452 B2 AU 2020233452B2
Authority
AU
Australia
Prior art keywords
thieno
compound
diffraction
crystal
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020233452A
Other languages
English (en)
Other versions
AU2020233452A1 (en
Inventor
Tamaki Hoshikawa
Ikuo Kushida
Yoshiaki Ohashi
Nobuaki Sato
Kenshi Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2020233452A1 publication Critical patent/AU2020233452A1/en
Application granted granted Critical
Publication of AU2020233452B2 publication Critical patent/AU2020233452B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020233452A 2019-03-05 2020-03-03 Salt of pentacyclic compound and crystals thereof Active AU2020233452B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019039349 2019-03-05
JP2019-039349 2019-03-05
PCT/JP2020/008889 WO2020179781A1 (ja) 2019-03-05 2020-03-03 五環式化合物の塩およびそれらの結晶

Publications (2)

Publication Number Publication Date
AU2020233452A1 AU2020233452A1 (en) 2021-09-02
AU2020233452B2 true AU2020233452B2 (en) 2025-04-10

Family

ID=72337486

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020233452A Active AU2020233452B2 (en) 2019-03-05 2020-03-03 Salt of pentacyclic compound and crystals thereof

Country Status (11)

Country Link
US (1) US11420980B2 (https=)
EP (1) EP3936189A4 (https=)
JP (1) JP7508441B2 (https=)
KR (1) KR102921161B1 (https=)
CN (1) CN113646046B (https=)
AU (1) AU2020233452B2 (https=)
BR (1) BR112021015979A2 (https=)
CA (1) CA3129764A1 (https=)
MX (1) MX2021009774A (https=)
TW (2) TWI870286B (https=)
WO (1) WO2020179781A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020179780A1 (ja) 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物
PT119624A (pt) * 2024-07-29 2026-01-29 Silva Escada Guilherme Máquina modular para a dobragem de tubos de pvc

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
EP0441517A2 (en) * 1990-02-08 1991-08-14 Pfizer Inc. Tricyclic amines as novel cholinesterase inhibitors
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5859016A (en) * 1995-06-20 1999-01-12 Je Il Pharmaceutical Co., Ltd. Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient
WO2004033666A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD258234A1 (de) 1987-03-05 1988-07-13 Univ Leipzig Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
AU2005299031B2 (en) 2004-10-20 2011-11-10 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
US9314318B2 (en) * 2008-08-26 2016-04-19 Zest Ip Holdings, Llc Dental anchor apparatus and method
JP6557441B1 (ja) * 2017-09-07 2019-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式化合物
WO2020179780A1 (ja) 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
EP0441517A2 (en) * 1990-02-08 1991-08-14 Pfizer Inc. Tricyclic amines as novel cholinesterase inhibitors
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5859016A (en) * 1995-06-20 1999-01-12 Je Il Pharmaceutical Co., Ltd. Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient
WO2004033666A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases

Also Published As

Publication number Publication date
EP3936189A1 (en) 2022-01-12
JP7508441B2 (ja) 2024-07-01
BR112021015979A2 (pt) 2021-10-05
KR20210135223A (ko) 2021-11-12
US11420980B2 (en) 2022-08-23
CN113646046A (zh) 2021-11-12
KR102921161B1 (ko) 2026-02-02
TWI849070B (zh) 2024-07-21
MX2021009774A (es) 2021-09-08
JPWO2020179781A1 (https=) 2020-09-10
CN113646046B (zh) 2024-05-17
AU2020233452A1 (en) 2021-09-02
EP3936189A4 (en) 2022-12-14
TW202430531A (zh) 2024-08-01
WO2020179781A1 (ja) 2020-09-10
TW202100531A (zh) 2021-01-01
US20210024541A1 (en) 2021-01-28
TWI870286B (zh) 2025-01-11
CA3129764A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
JP5599610B2 (ja) Ｈｓｐ９０の阻害による神経変性疾患の処置
US10239889B1 (en) Pentacyclic compound
CN104039786A (zh) 用于治疗脆性x综合征的pak抑制剂
AU2020233452B2 (en) Salt of pentacyclic compound and crystals thereof
RU2736123C1 (ru) Производные 2-аминохиназолина в качестве ингибиторов p70s6 киназы
ES2948767T3 (es) Moléculas orgánicas pequeñas para uso en el tratamiento de trastornos neuroinflamatorios
RU2820938C2 (ru) Соль пентациклического соединения и его кристалл
KR102352624B1 (ko) LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
JP2001002572A (ja) ニューロトロフィン作用増強剤
BR112020003197B1 (pt) Composto pentacíclico
HK40022802B (en) Pentacyclic compound
HK40022802A (en) Pentacyclic compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)